DNA repair after irradiation in glioma cells and normal human astrocytes

Neuro-Oncology

Volumn 9, Issue 4, 2007, Pages 404-411

  Short, Susan C ^a   Martindale, Christine ^a   Bourne, Sara ^a   Brand, Geoff ^b   Woodcock, Mick ^b   Johnston, Peter ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Gray Cancer Institute   (United Kingdom)

Author keywords

Astrocyte; DNA repair; Glioma; Radiation; Radiosensitivity

Indexed keywords

CAFFEINE; DOUBLE STRANDED DNA; HISTONE H2AX; RAD51 PROTEIN;

ARTICLE; ASTROCYTE; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE PARAMETERS; CELL CYCLE PHASE; CELL CYCLE S PHASE; CELL LABELING; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; FLUORESCENCE; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IRRADIATION; MITOSIS RATE; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIOSENSITIZATION; WESTERN BLOTTING; BIOSYNTHESIS; DOUBLE STRANDED DNA BREAK; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; GLIOMA; PHYSIOLOGY; RADIATION EXPOSURE; RADIATION RESPONSE; TUMOR CELL LINE;

ASTROCYTES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLUORESCENT ANTIBODY TECHNIQUE; GLIOMA; HUMANS; RAD51 RECOMBINASE; RADIATION TOLERANCE;

EID: 36949025036     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2007-030     Document Type: Article

References (36)

1. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6:509-518.
2. Prados MD, Scott C, Sandler H, et al. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404. Int J Radiat Oncol Biol Phys. 1999;45:1109-1115.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
4. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs. 1997;8:92-97.
5. van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys. 2000;47:779-784.
6. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352:997-1003.
7. Nutley BP, Smith NF, Hayes A, et al. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br J Cancer. 2005;93:1011-1018.
8. Lara PN Jr, Mack PC, Synold T, et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California Cancer Consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res. 2005;11:4444-4450.
9. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastomas. Am J Pathol. 2007;170:1445-1453.
10. Broaddus WC, Liu Y, Steele LL, et al. Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction. J Neurosurg. 1999;91:997-1004.
11. Mazzatti DJ, Lee YJ, Helt CE, O'Reilly MA, Keng PC. p53 modulates radiation sensitivity independent of p21 transcriptional activation. Am J Clin Oncol. 2005;28:43-50.
12. Kim JS, Krasieva TB, Kurumizaka H, Chen DJ, Taylor AM, Yokomori K. Independent and sequential recruitment of NHEJ and HR factors to DNA damage sites in mammalian cells. J Cell Biol. 2005;170:341-347.
13. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res. 2002;62:219-225.
14. Linke SP, Sengupta S, Khabie N, et al. p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res. 2003;63:2596-2605.
15. Yoon D, Wang Y, Stapleford K, Wiesmuller L, Chen J. P53 inhibits strand exchange and replication fork regression promoted by human Rad51. J Mol Biol. 2004;336:639-654.
16. Golding SE, Rosenberg E, Khalil A, et al. Double strand break repair by homologous recombination is regulated by cell cycle-independent signaling via ATM in human glioma cells. J Biol Chem. 2004; 279:15402-15410.
17. Ohnishi T, Taki T, Hiraga S, Arita N, Morita T. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Commun. 1998;245:319-324.
18. Russell JS, Brady K, Burgan WE, et al. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res. 2003;63:7377-7383.
19. Lees-Miller SP, Godbout R, Chan DW, et al. Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line. Science. 1995;267:1183-1185.
20. Daido S, Yamamoto A, Fujiwara K, Sawaya R, Kondo S, Kondo Y. Inhibition of the DNA-dependent protein kinase catalytic subunit radio-sensitizes malignant glioma cells by inducing autophagy. Cancer Res. 2005;65:4368-4375.
21. Short SC, Bourne S, Martindale C, Woodcock M, Jackson SP. DNA damage responses at low radiation doses. Radiat Res. 2005;164:292-302.
22. van Veelen LR, Cervelli T, van de Rakt MW, Theil AF, Essers J, Kanaar R. Analysis of ionizing radiation-induced foci of DNA damage repair proteins. Mutat Res. 2005;574:22-33.
23. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273:5858-5868.
24. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol. 2000;10:886-895.
25. Takahashi A, Ohnishi T. Does H2AX foci formation depend on the presence of DNA double strand breaks? Cancer Lett. 2005;229:171-179.
26. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, et al. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol. 2003;5:675-679.
27. Short S, Mayes C, Woodcock M, Johns H, Joiner MC. Low dose hyper-sensitivity in the T98G human glioblastoma cell line. Int J Radiat Biol. 1999;75:847-855.
28. Foray N, Arlett CF, Malaise EP. Underestimation of the small residual damage when measuring DNA double-strand breaks (DSB): is the repair of radiation-induced DSB complete? Int J Radiat Biol. 1999;75:1589-1595.
29. Brammer I, Herskind C, Haase O, Rodemann HP, Dikomey E. Induction and repair of radiation-induced DNA double-strand breaks in human fibroblasts are not affected by terminal differentiation. DNA Repair (Amst). 2004;3:113-120.
30. Vispe S, Cazaux C, Lesca C, Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res. 1998;26:2859-2864.
31. Yamamoto A, Taki T, Yagi H, et al. Cell cycle-dependent expression of the mouse Rad51 gene in proliferating cells. Mol Gen Genet. 1996;251:1-12.
32. Esashi F, Christ N, Gannon J, et al. CDK dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature. 2005;434:598-604.
33. Chen Z, Xiao Z, Gu W, et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer. 2006;2006;119:2784-2794.
34. Keogh MC, Kim JA, Downey M, et al. A phosphatase complex that dephosphorylates H2AX regulates DNA damage checkpoint recovery. Nature. 2006;439:497-501.
35. Johnston PJ, Woodcock M, Gregory HC, et al. The role of cell cycle checkpoint control in the response to low doses of ionising radiation [abstract]. In: Cooper, R, et al., eds. Twelfth International Congress of Radiation Research, Brisbane, Australia: Book of Abstracts. New South Wales, Australia: Australian Institute of Nuclear Science and Engineering; 2003:329.
36. Henning W, Sturzbecher HW. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology. 2003;193:91-109.